Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 26, 2023

BUY
$68.48 - $81.09 $11,573 - $13,704
169 Added 2.26%
7,632 $549,000
Q3 2022

Oct 20, 2022

BUY
$0.13 - $76.84 $4 - $2,766
36 Added 0.48%
7,463 $531,000
Q2 2022

Aug 10, 2022

BUY
$72.62 - $79.98 $42,845 - $47,188
590 Added 8.63%
7,427 $572,000
Q1 2022

May 16, 2022

SELL
$61.48 - $73.72 $58,897 - $70,623
-958 Reduced 12.29%
6,837 $499,000
Q4 2021

Jan 31, 2022

BUY
$53.63 - $62.52 $21,988 - $25,633
410 Added 5.55%
7,795 $486,000
Q3 2021

Nov 12, 2021

BUY
$59.17 - $69.31 $473 - $554
8 Added 0.11%
7,385 $437,000
Q2 2021

Aug 19, 2021

BUY
$61.91 - $67.42 $30,026 - $32,698
485 Added 7.04%
7,377 $492,000
Q1 2021

May 14, 2021

BUY
$59.34 - $66.74 $59 - $66
1 Added 0.01%
6,892 $435,000
Q4 2020

Feb 05, 2021

BUY
$57.74 - $65.43 $397,886 - $450,878
6,891 New
6,891 $427,000
Q1 2019

May 03, 2019

SELL
$45.12 - $53.8 $3.09 Million - $3.68 Million
-68,383 Closed
0 $0
Q4 2018

Jan 25, 2019

SELL
$48.76 - $63.23 $1.06 Million - $1.38 Million
-21,766 Reduced 24.14%
68,383 $3.56 Million
Q3 2018

Nov 01, 2018

SELL
$55.19 - $62.25 $451,178 - $508,893
-8,175 Reduced 8.31%
90,149 $5.6 Million
Q2 2018

Aug 06, 2018

SELL
$50.53 - $62.98 $226,424 - $282,213
-4,481 Reduced 4.36%
98,324 $5.44 Million
Q1 2018

Apr 26, 2018

BUY
$59.92 - $68.98 $66,211 - $76,222
1,105 Added 1.09%
102,805 $6.5 Million
Q4 2017

Feb 07, 2018

BUY
$59.94 - $65.35 $303,356 - $330,736
5,061 Added 5.24%
101,700 $6.23 Million
Q3 2017

Nov 13, 2017

SELL
$55.23 - $63.74 $16,016 - $18,484
-290 Reduced 0.3%
96,639 $6.16 Million
Q2 2017

Aug 14, 2017

BUY
N/A
96,929
96,929 $5.4 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Boston Common Asset Management, LLC Portfolio

Follow Boston Common Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boston Common Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boston Common Asset Management, LLC with notifications on news.